BOEHRINGER INGELHEIM RCV GMBH CO KG
A stranger
Adaptmet: Deconstructing adaptive evolution of metastasis
Adaptmet aims to develop an advanced training program encompassing the multifaceted aspects of metastasis adaptation mechanisms, intending t...
2024-07-05 - 2029-02-28 | financed
2024-07-05 - 2029-02-28 | financed
Evomet: Deconstructing the evolution of metastasis
BOEHRINGER INGELHEIM RCV GMBH CO KG
participó en un
H2020:
H2020-MSCA-ITN-2020
Evomet aims to create a high-level training programme on the various aspects of metastasis evolution in order to provide young researchers w...
2020-09-03 - 2025-02-28 | financed
2020-09-03 - 2025-02-28 | financed
Secreters: A new generation of microbial expression hosts and tools for the production of biotherapeutics and h...
BOEHRINGER INGELHEIM RCV GMBH CO KG
participó en un
H2020:
H2020-MSCA-ITN-2018
The ‘SECRETERS’ partnership aims to bring about a step change in the production of recombinant proteins, particularly Biotherapeutics and In...
2018-08-30 - 2023-06-30 | financed
2018-08-30 - 2023-06-30 | financed
META-CAN: Targeting the metabolism immune system connections in Cancer
BOEHRINGER INGELHEIM RCV GMBH CO KG
participó en un
H2020:
H2020-MSCA-ITN-2017
"Cancer cells show common features of profound metabolic changes and escape from the immune system, independently of their tissue of origin....
2017-08-10 - 2021-08-31 | financed
2017-08-10 - 2021-08-31 | financed
* No data from the current company are not available.